Kornimate/medical-research-clean huggingface dataset:
irinotecan and temozolomide in combination with existing high dose alkylator based chemotherapy for treatment of patients with newly diagnosed ewing sarcoma

Conditions: Newly Diagnosed Ewing Sarcoma

Summary: the purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on ewing sarcoma. irinotecan and temozolomide are chemotherapy drugs that are used very often to treat pediatric patients at mskcc. the investigators have used these two drugs for many years to treat patients with ewing sarcoma whose cancer has relapsed. for patients with newly diagnosed ewing sarcoma the current standard of care at mskcc is a five drug chemotherapy regimen in combination with surgery and/or radiation therapy. this standard regimen is called the eft regimen. . some patients with ewing sarcoma do not have their cancer cured by the chemotherapy and surgery/radiation therapy. this study adds the chemotherapy drugs called irinotecan and temozolomide to the standard eft regimen. the investigators are trying to improve the success of standard therapy by adding these drugs. the use of irinotecan and temozolomide in this study is experimental because they have not been used before in patients with newly diagnosed ewing sarcoma. however the investigators have found these drugs to be effective in patients with relapsed ewing sarcoma. it is not known if adding these two drugs will improve the outcomes of patients treated for ewing sarcoma.


Eligibility criteria:
inclusion criteria: * age greater than or equal to one year and less than or equal to 40 years at the time of diagnosis * newly diagnosed, previously untreated patients with histologically or molecularly confirmed ewing sarcoma * adequate hematologic function: * absolute neutrophil count ≥ 1,000/k/mcl * platelet count ≥ 100,000/kmcl * adequate renal function: * normal creatinine for age (see table below) or * creatinine clearance or radioisotope gfr ≥ 70ml/min/1.73 m2 age(years) maximum serum creatinine (mg/dl) ≤ 5 0.8 6 to ≤ 10 1 11 to ≤ 15 1.2 ≥ 16 1.5 adequate hepatic function: * total bilirubin ≤ 1.5 x the uln * ast ≤ 2.5 x the uln \[in the absence of hepatic involvement of tumor. patients with hepatic involvement are considered eligibile for study\] * alt ≤ 2.5 x the uln \[in the absence of hepatic involvement of tumor. patients with hepatic involvement are considered eligibile for study\] normal cardiac function: * shortening fraction ≥ 28% by echocardiogram or * left ventricular ejection fraction (lvef) ≥ 50% on technetium- 99m pertechnetate radionuclide cineangiography (muga) or echocardiogram * patients must consent to an indwelling central venous catheter. * sexually active patients of reproductive potential must be willing to use an effective method of contraception. exclusion criteria: * prior chemotherapy or radiotherapy (other than limited, emergent radiotherapy for treatment of eg. spinal cord compromise or threatened airway) * pregnant or breastfeeding females

Keywords: cyclophosphamide (cytoxan) doxorubicin/adriamycin etoposide (vp-16) ifosfamide irinotecan (cpt-11) camptosar temozolomide vincristine 13-068
retreatment with ctl019/ctl119

Conditions: Lymphoma, B-Cell

Summary: this research study is designed to evaluate the effects of retreatment with ctl019/ctl119 in patients with late relapse of b-cell lymphomas.

this is a single arm open label trial that will assess the safety and efficacy of retreatment with ctl019/ctl119 chimeric antigen receptor (car) modified t cells in patients who have late relapse of diffuse large b-cell or follicular lymphoma after achieving complete remission from prior ctl019/ctl119 treatment. patients eligible for this protocol will have been treated initially with ctl019/ctl119 under upcc13413/nct02030834, have experienced a durable complete response (defined as ≥ 6 months duration), and have a residual manufactured ctl019/ctl119 product available. this protocol will serve subjects with no available potentially curative treatment options (such as autologous or allogeneic stem cell transplantation) who have a limited prognosis (months to \< 2 year expected survival) with available therapies.

Eligibility criteria:
inclusion criteria: 1. diffuse large b-cell lymphoma or follicular lymphoma, previously identified as cd19+ 2. previously treated on upcc13413/ nct02030834 with ctl019/ctl119, with historical manufactured product available at penn for reinfusion 3. previous complete response to car t-cells with a duration ≥ 6 months (defined as 168 days) 4. no available curative treatment options (such as autologous or allogeneic hsct) with limited prognosis (several months to \< 2 year survival) with currently available therapies. 5. age ≥18 years 6. creatinine \< 1.6 mg/dl 7. alt/ast \< 3x upper limit of normal 8. bilirubin \< 2.0 mg/dl, unless subject has gilbert's syndrome (≤3.0 mg/dl) 9. measurable or assessable disease according to the "revised response criteria for malignant lymphoma" (cheson et al., j. clin. onc., 2007)88. patients in complete remission with no evidence of disease are not eligible. 10. performance status (ecog) 0 or 1. 11. left ventricle ejection fraction (lvef) \> 40% confirmed by echo/muga 12. agree to contraceptive requirements outlined in section 4.3. 13. provide written informed consent. exclusion criteria: 1. uncontrolled active infection. 2. active hepatitis b or hepatitis c infection. 3. any uncontrolled active medical disorder that would preclude participation as outlined. 4. class iii/iv cardiovascular disability according to the new york heart association classification (see appendix 1). 5. hiv infection. 6. patients with active cns involvement by malignancy. patients with prior cns disease that has been effectively treated will be eligible providing treatment was \>4 weeks before enrollment 7. patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Keywords: ctl019 ctl119 car t-cell cart
improving short course treatment for common pediatric infections

Conditions: Community-acquired Pneumonia; Skin Infection

Summary: randomized quality improvement trial to improve the proportion of cases of community-acquired pneumonia (cap) treated with no more than 5 days of antibiotics the proportion of cases of skin and soft tissue infections (ssti) treated with no more than 7 days of antibiotics by primary care clinicians (pcc) within the pediatric physicians' organization at children's (ppoc), a state-wide pediatric primary care network. interventions include education and feedback; clinical decision support (cds) delivered at the point of care; and the combination of the two.


Eligibility criteria:
inclusion criteria * primary care clinician practicing within a ppoc primary care pediatric practice * treated at least one case of pneumonia or skin and soft tissue infection in calendar year 2022 exclusion criteria -none
prostaglandin and cannabinoid receptors in eoe

Conditions: Eosinophilic Esophagitis (EoE)

Summary: the purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (eoe). a prostaglandin d2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in eoe. prostaglandin d2 and e2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for eoe development. the prostaglandin d2 and e2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of eoe.

prostaglandin d2 and e2 receptors, and components of the endocannabinoid system (cannabinoid receptors and endocannabinoid-metabolizing enzymes) are examined in mucosal esophageal biopsies and blood leukocytes from eoe patients (acute and in remission), individuals with gastroesophageal reflux and from individuals with no esophageal disease. expression of these components are compared between all cohorts by polymerase chain reaction, western blots, flow cytometry and immunohistochemical methods. eoe disease activity is evaluated by determining a symptom score and the number of eosinophils per high-power field (hpf) in histologic sections of mucosal biopsies. additionally, an endoscopic reference score (erefs) is used. disease activity is correlated with cannabinoid/prostaglandin d2 and e2 receptor expression. blood is collected and immediately processed for flow cytometric experiments. prostaglandins and endocannabinoids are measured in plasma and esophageal mucosal biopsy samples of all cohorts by mass spectrometry.

Eligibility criteria:
inclusion criteria: * diagnosed or suspected eoe or gerd * without esophageal diseases * with signed informed consent exclusion criteria: * viral or parasitic diseases (e.g. herpes, candidiasis) * eosinophilic gastroenteritis, hypereosinophilic syndrome, crohn's disease * autoimmune diseases * unable to give informed consent * immunosuppressive therapy
pilot study of neo-adjuvant everolimus to treat advanced renal cell carcinoma - analysis of biomarkers

Conditions: Carcinoma, Renal Cell

Summary: this study will gather data on potential biomarkers in the treatment of advanced renal cell carcinoma (kidney cancer) and investigate their use as indicators of disease response. the results could eventually enable doctors to match levels of therapy to levels of biomarker on an individual basis and to increase the chance of disease response in patients. this study will also test a new paradigm in the treatment approach of advanced kidney cancer by using the drug everolimus in a neo-adjuvant setting, with the overarching goal of decreasing cancer recurrence rates and improving patient outcomes and survival.


Eligibility criteria:
inclusion criteria: * at least 18 years of age and capable of giving informed consent * radiological evidence of rcc consisting of: ct scan with stage t2, t3, t3a, t3b, t4, or any stage t with n1/ 2 and/ or metastatic disease * having a nephrectomy and willing to have a kidney biopsy * ecog score 0 or 1 * clear cell histology * negative for hiv, hepatitis b, and hepatitis c * negative pregnancy test for women of child-bearing potential exclusion criteria: * stage t1 disease without metastases * abnormal laboratory values at screening within the following ranges: * absolute neutrophil count ≤ 1.5 × 109/ l; platelet count ≤ 100 × 109/ l * leukocyte count ≤ 3 × 109/ l; hemoglobin ≤ 80 g/ l; serum creatinine ≥ 2.0 × the upper normal limit (unl); total bilirubin ≤ 1.5 × unl; ast and alt ≤ 3.0 × unl * fasting serum cholesterol ≤ 9.0 mmol/ l; fasting serum triglycerides ≥ 5.0 mmol/l * any major illness that, based on the investigator's judgment, will substantially increase the risk associated with a subject's participation in this study * other currently active malignancies * currently taking any medications known to interfere with the metabolism of everolimus * receiving anticoagulation with warfarin * a history of pulmonary hypertension or interstitial lung disease

Keywords: renal cell carcinoma metastatic everolimus neo-adjuvant biomarkers nephrectomy locally advanced clear cell renal carcinoma metastatic clear cell renal carcinoma clear cell renal carcinoma
blood glucose monitoring system clinical study

Conditions: Diabetes

Summary: verify the following with blood glucose monitoring system: * precision and accuracy versus ysi reference * user evaluation * labeling comprehension


Eligibility criteria:
inclusion criteria: * be diagnosed with diabetes * be between 12 and 70 years of age * be able to read, write, and understand english * be able and willing to give informed consent * have used an smbg meter system for at least one year * be currently testing blood glucose levels at least once per day exclusion criteria: * inability to provide informed consent * subject does not meet inclusion criteria * subject does not agree to test for infectious diseases per clinical protocol * subject has minimally one positive test for any infectious disease listed under exclusion criteria per protocol * subject with any condition (in addition to those which are listed in the pre-screen exclusion criteria tests) which in the opinion of the investigator may place the subject or site personnel at excessive risk * subject's physical condition/limitation prevents the person from using a bgms on their own
the pcos challenge study

Conditions: Polycystic Ovary Syndrome

Summary: the primary purpose of the pcos challenge study will be to conduct high-quality research where patients are included in the design, and answering the questions that patients identify as important to their lived experience with pcos. in partnership with clinical investigators, patients will work on the development and management of data collection, the research agenda, and the sharing of research findings. the pcosc study will promote the advancement of research that provides reliable, useful, and meaningful information to patients with pcos and their clinicians. the population for the pcos challenge study will include individuals with a clinical diagnosis of pcos, individuals self-diagnosed with pcos, individuals with symptoms of pcos (e.g., hirsutism, irregular menstrual cycles), and demographic-matched controls without pcos.


Eligibility criteria:
inclusion criteria: * diagnosed with pcos by a health professional, self-diagnosed with pcos or individuals with pcos symptoms * willing to sign the consent form * able to understand the registry surveys or what is being asked exclusion criteria: * unable to understand the surveys or what is being asked * unwilling to sign the consent form

Keywords: pcos polycystic ovary syndrome polycystic ovarian syndrome stein leventhal syndrome
endoscopic retrograde cholangiopancreatography (ercp) based sampling of indeterminate bile duct strictures

Conditions: Indeterminate Bile Duct Stricture

Summary: differentiating malignant from benign bile duct strictures is a conundrum, since no diagnostic test is highly sensitive for diagnosing cancer. while ercp is effective in palliating obstructive jaundice, standard diagnostic tools in ercp have a low diagnostic sensitivity and confirm the stricture's etiology in \<50% of cases. during the first ercp, standard practice is to obtain routine cytology (rc) using a single brush sample. if this is not diagnostic, patients often undergo repeat ercp, endoscopic ultrasound or other, increasing health care costs. the incremental yield of performing alternate ercp-based diagnostic tools during the first ercp including fluorescence in situ hybridization (fish), cholangioscopy w/biopsy and multiple brushes for routine cytology is currently unknown. there are no studies quantifying the amount of testing utilized to firmly diagnose the etiology of the stricture, or the most efficient combination of diagnostic tools during the first ercp. these are important knowledge deficiencies since a definitive tissue diagnosis during the first ercp could reduce the need for downstream tests and expedite treatment, thereby improving patient-centered and economic outcomes. the added costs of using multiple tools during the first ercp may be offset by these benefits. among patients with indeterminate bile duct strictures, the investigators hypothesize that a multimodality approach will be more sensitive without a significant reduction in specificity compared to multiple brush samples for routine cytology. the investigators will test this hypothesis using an experimental trial design by randomizing patients during their first ercp to multiple brushing samples for cytology vs. a single brush sample for cytology + fish + cholangioscopy w/biopsy. to obtain preliminary data for a definitive multi-center trial, the investigators propose a pilot and feasibility study to compare the performance characteristics of each approach by evaluating the prospective clinical course, including treatment delay, quality of life, and life expectancy for each enrolled patient. if our hypothesis is validated in a subsequent definitive study, the standard approach to tissue sampling during the first ercp may be altered.


Eligibility criteria:
inclusion criteria: * extrahepatic bds with no discrete mass on ct/mri (either or both) * a bds is defined as a segmental narrowing of the bile duct \> 50% of the proximal or distal unaffected duct. * biochemical evidence of cholestasis (increase in alkaline phosphatase ≥ 2x upper limit of normal ± total bilirubin ≥2.0mg/dl) exclusion criteria: * no clinical suspicion for malignancy * associated mass seen on ct or mri * age ≤18, pregnancy, incarceration, inability to give informed consent * inability to undergo standard ercp (e.g., postsurgical anatomy) * previous ercp with sampling of bds, other than a single brushing specimen sent for routine cytopathology

Keywords: stricture cholangiocarcinoma pancreatic adenocarcinoma bile duct ercp
multicenter study on laparoscopic distal subtotal gastrectomy for advanced gastric cancer (class-01)

Conditions: Stomach Neoplasms

Summary: * laparoscopic distal subtotal gastrectomy with lymph node dissection as minimally invasive surgery has gained popularity for the treatment of early gastric cancer in east asian countries, even though the long-term follow-up outcome based on multicenter randomized clinical trial (rct) is still awaited. * for the patient with locally advanced gastric cancer, several studies indicated that laparoscopic distal subtotal gastrectomy with d2 lymphadenectomy is a technically feasible and safe procedure by experienced surgeons in high-volume specialized hospitals. however, the application of it is controversial mainly due to lack of solid evidence on the oncologic efficacy. therefore, conventional open approach is still the current standard for advanced gastric cancer. * nowadays, the proportion of patients with locally advanced gastric cancer is estimated up to 80 per cent of all gastric cancer cases in china. before the clinical application of laparoscopic procedure for the treatment with curative intent to advanced gastric cancer located at the middle- or lower-third of the stomach, the oncologic efficacy must be verified. * accordingly,the comparison of intraoperative and postoperative complications between laparoscopic and open distal subtotal gastrectomy for over 65 years old patients with gastric cancer based on a randomized controlled trial is needed.


Eligibility criteria:
inclusion criteria: * age from over 18 to under 75 years * primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy * ct2-4a, n0-3, m0 at preoperative evaluation according to the ajcc cancer staging manual seventh edition * expected curative resection through distal subtotal gastrectomy with d2 lymphadenectomy * performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale * asa (american society of anesthesiology) score class i, ii, or iii * written informed consent exclusion criteria: * women during pregnancy or breast-feeding * severe mental disorder * history of previous upper abdominal surgery (except laparoscopic cholecystectomy) * history of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection * enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging * history of other malignant disease within past five years * history of previous neoadjuvant chemotherapy or radiotherapy * history of unstable angina or myocardial infarction within past six months * history of cerebrovascular accident within past six months * history of continuous systematic administration of corticosteroids within one month * requirement of simultaneous surgery for other disease * emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * fev1\<50% of predicted values

Keywords: stomach neoplasms laparoscopy
pattern of admission and outcome of patients admitted to the intensive care

Conditions: Respiratory Failure; Treatment Outcome

Summary: the study was a retrospective observational cohort where patient medical record review was done and data were gathered on 419 cases. the icu admission pattern and patient outcome were the primary outcomes presented in the manuscript.

the study was conducted at a teaching university hospital in a low-resource setting retrospectively on admission to icu over the last five years. samples were selected using a simple random sampling technique to come up with the desired number.

Eligibility criteria:
inclusion criteria: * complete medical record * admission to icu exclusion criteria: * patients who were transferred or self discharged
integration and interactions between visual and proprioceptive feedbacks

Conditions: Hemiparetic Stroke

Summary: mental imagery is a rehabilitation technique for stroke patients, involving the mental representation of movement. recent technical advancements have enabled the use of visual, proprioceptive, and mixed feedback to enhance motor stimulation. currently, all post-stroke patients receive these techniques indiscriminately. this study aims to demonstrate differences in the integration of visual and proprioceptive feedback in stroke patients and understand the determinants based on the affected brain area. patients with motor disabilities will perform motor imagery tasks with various feedback types while their cortical activity is recorded using eeg. eeg data for each type of feedback will be correlated with the lesion area in order to better understand the ongoing mechanisms.


Eligibility criteria:
inclusion criteria: * hemiplegic subjects : male or female, aged 18 to 80 years, first ischemic or hemorrhagic stroke, having signed the written consent and affiliated or entitled to a social security scheme exclusion criteria: * severe cognitive impairment, severe aphasia or severe neglect that impair ability to understand instructions or to execute tasks

Keywords: computerize mirror vibration upper limb rehabilitation stroke hemiplegic
high risk breast cancer screening program

Conditions: Breast Cancer

Summary: objectives: * to screen population with high risk for breast cancer * to promote the concept and importance of surveillance mammography * to find out the incidence of breast cancer in population who are in high risk for breast cancer * to collect blood samples for molecular analysis


Eligibility criteria:
inclusion criteria: * female * \> 40 years of age * women who have first-degree relative suffered from breast cancer * women who have first-degree relative suffered from ovarian cancer * family history of male breast cancer * family history of breast cancer (not necessarily first degree relatives) diagnosed before age of 40 * family history of breast cancer (not necessarily first degree relatives) affecting 2 or more family members * personal history of ovarian cancer * personal history of premalignant conditions of breast and ovary exclusion criteria: * women with mammogram within one year

Keywords: hereditary breast cancer (brca1, brca2)